Fig. 3: Interleukin-3 protects against viral infection by increasing pDC numbers in the lungs.
From: Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
a Percentage of pDCs in BALF of patients with pulmonary diseases with high or low BALF IL-3 levels. p = 0.004. Mann–Whitney test. n = 12. b Absolute numbers of pDCs and neutrophils in the lungs of naive mice 24 h after the i.n. injection of PBS or rIL-3, followed by an i.n. injection of CpG 8 h later. p = 0.0091. n = 8. c Levels of IFNα and IFNλ in the BALF of naive mice that received an i.n. injection of PBS or rIL-3, followed by an i.n. injection of CpG 8 h later, and were sacrificed 16 h later. n = 14 for IFNα (p = 0.0205) and n = 22 for IFNλ (p = 0.018). d, e Survival (d) and viral load in the lungs (e) of naive WT mice after i.n. infection with 6 × 106 PFU of HSV-1. Mice received an i.n. injection of PBS or rIL-3 just before HSV-1 infection. n = 26 (d) and n = 19 for d1 (p = 0.0151) and n = 15 for d3 (p = 0.0439) (e). Data are mean ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001, unpaired, two-tailed Student’s t test using Welch’s correction for unequal variances was used. Source data are provided as a Source Data file.
